Antimicrobial Agents and Chemotherapy, October 2001, p. 2781-2786, Vol. 45, No. 10
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.10.2781-2786.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Laboratory of Mycology Research, Division of Infectious Diseases, Department of Internal Medicine, and Center for the Study of Emerging and Re-emerging Pathogens, University of Texas Houston Medical School, Houston, Texas 77030,1 and Aronex Pharmaceuticals, The Woodlands, Texas 773812
Received 1 February 2001/Returned for modification 31 May 2001/Accepted 19 July 2001
When nystatin is placed in RPMI and other biological fluids, there
is loss of pure nystatin, with the development of two distinguishable chromatographic peaks, 1 and 2. Peak 1 appears identical to
commercially prepared nystatin. By nuclear magnetic resonance (NMR) and
mass spectral analysis, peak 2 appears to be an isomer of peak 1. The isomers are quantitatively and fully interconvertible. Formation of
peak 2 is accelerated at a pH of >7.0 and ultimately reaches a near
55:45 (peak 1/peak 2 ratio) mixture. We sought to determine the
relative activities of peaks 1 and 2 against Candida
spp. Peak 2 consistently showed higher MICs when it was the predominant form during the experiment. Time-kill analyses showed that peak 2 required
8× the concentration of peak 1 to produce a modest and
delayed killing effect, which was never of the same magnitude as that
produced by peak 1. In both types of assays, the activity of peak 2 corresponded with intra-assay formation of peak 1. Both MIC
measurements and time-kill analysis suggest that peak 2 has considerably less activity, if any at all, against
Candida spp. Peak 2 may serve as a reservoir for peak 1.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |